Abstract
Mutations in the LRRK2 gene have been implicated in the pathogenesis of Parkinsons disease. This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinsons disease-associated mutants do not appear to have reduced GTP hydrolysis activities.
Keywords: LRRK2, ROC domain, small GTPase, GTP binding, Parkinson's disease
Protein & Peptide Letters
Title: The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein
Volume: 16 Issue: 12
Author(s): Qing-Shan Fu, Ai-Xin Song, Su-Xia Li and Hong-Yu Hu
Affiliation:
Keywords: LRRK2, ROC domain, small GTPase, GTP binding, Parkinson's disease
Abstract: Mutations in the LRRK2 gene have been implicated in the pathogenesis of Parkinsons disease. This work provides biochemical evidence that the ROC domain of LRRK2 functions as a small GTPase, and the Parkinsons disease-associated mutants do not appear to have reduced GTP hydrolysis activities.
Export Options
About this article
Cite this article as:
Fu Qing-Shan, Song Ai-Xin, Li Su-Xia and Hu Hong-Yu, The Small GTPase Activity of the ROC Domain from LRRK2, a Parkinsons Disease Related Protein, Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839386
DOI https://dx.doi.org/10.2174/092986609789839386 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease
CNS & Neurological Disorders - Drug Targets Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Preface
Current Drug Targets - CNS & Neurological Disorders Do mtDNA Mutations Participate in the Pathogenesis of Sporadic Parkinsons Disease?
Current Genomics Palmitoylethanolamide Regulates Production of Pro-Angiogenic Mediators in a Model of β Amyloid-Induced Astrogliosis <i>In Vitro</i>
CNS & Neurological Disorders - Drug Targets Cell Culture Models of Oxidative Stress and Injury in the Central Nervous System
Current Neurovascular Research Shoulder Manifestations of Diabetes Mellitus
Current Diabetes Reviews Influence of Lithium Treatment on GDNF Serum and CSF Concentrations in Patients with Early Alzheimers Disease
Current Alzheimer Research Protein Aggregation in Neurodegenerative Diseases: Insights from Computational Analyses
Current Bioinformatics Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design A Genomic and Epigenomic Approach for Studying Neuropsychiatric Disorders Associated to Early-life Stress: Part II
Current Genomics Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Current Progress of Reelin in Development, Inflammation and Tissue Remodeling: From Nervous to Visual Systems
Current Molecular Medicine Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Modeling Parkinson’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Recent Developments in the Understanding and Treatment of Neurodegenerative Disorders Involving Protein Conformational Misfolding and Amyloid Formation
Medicinal Chemistry Reviews - Online (Discontinued) Tryptophan Catabolites and Migraine
Current Pharmaceutical Design Glaucoma and Aging
Current Aging Science The Interface Between Alzheimers Disease, Normal Aging, and Related Disorders
Current Aging Science The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents